Navigation Links
Targeting des B-Zell-Rezeptors in aggressiven B-Zell-Lymphomen
Date:6/14/2013

STOCKHOLM, June 14, 2013 /PRNewswire/ --

Dr. Wyndham Wilson wird über aktuelle Entwicklungen bei der Behandlung von Lymphomen mit kleinen Molekülen berichten.

Obwohl in den vergangenen 30 Jahren eine wahre Fülle an Optionen zur Behandlung von diffusen großzelligen B-Zell-Lymphomen (DLBCL) entstanden ist, sind in diesem Bereich nur geringe Fortschritte erzielt worden. Aus neuesten Studien geht hervor, dass die Signalübertragung des B-Zell-Rezeptors für viele B-Zell-Lymphome ein entscheidender Faktor ist, darunter auch für den häufigsten Rezeptortyp - die sogenannten diffusen großzelligen B-Zell-Lymphome (DLBCL). Neueste Studien haben gezeigt, dass es sich bei DLBCL eigentlich um keine einzelne, sondern um mindestens 3 verschiedene Krankheiten handelt, von denen jede ganz eigene kritische Abnormalitäten aufweist, die das Überleben eines bösartigen Tumors begünstigen. Die am schwierigsten zu behandelnde Art von DLBCL wird als ABC-Subtyp (Activated B-cell) bezeichnet und hängt von einer abnormalen Signalübertragung des B-Zell-Rezeptors (BCR) ab. Untersuchungen von Dr. Lou Staudt haben gezeigt, dass derartige Tumoren absterben, sobald dieser Signaltransduktionsweg blockiert wird.

In Zusammenarbeit mit Dr. Lou Staudt, Pharmacyclics und Forschungskollegen haben wir eine klinische Studie eines äußerst potenten Inhibitors der Bruton-Tyrosinkinase (BTK) namens Ibrutinib durchgeführt. Die Hemmung der BTK durch Ibrutinib blockiert die abnormale BCR-Signalübertragung in ABC-DLBCL-Tumorzellen und tötet diese ab. In einer weiteren klinischen Studie, die mein Kollege im Zuge dieser EHA-Tagung präsentieren wird, zeigen wir, dass Tumoren von ABC-DLBCL-Patienten mithilfe von Ibrutinib abgetötet werden können. Noch wichtiger ist aber, das
'/>"/>

SOURCE European Hematology Association
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Aperture Health, Inc., Targeting the Strong Growth in the Long Term Disease Management arena
2. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
3. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
4. Cancer Cell Article Demonstrates First Definitive Evidence for Targeting of Pol I as New Approach to Cancer Therapy
5. 3-V Biosciences Presents Positive Preclinical Data on HCV Product Candidates Targeting FASN at the American Association for the Study of Liver Disease Annual Meeting 2012
6. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
7. Allazo Health CEO at Wharton Health Care Conference Shows how Predictive Analytics and Individualized Intervention Targeting Promote Medication Adherence.
8. XCHC Releases Worldwide Growth Guidance For Its Cannabinoid Treatment Centers and Formulations Targeting Critical Human Ailments, Company Acts on Own Guidance
9. Lithera Initiates Phase 2b Clinical Trial of LIPO-202 Targeting Aesthetic Reduction of Subcutaneous Abdominal Fat
10. Isis Publishes Data Demonstrating Antisense Targeting of ApoC-III Significantly Reduces ApoC-III and Triglycerides
11. Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Emerus Holdings, a national and innovative ... diagnostic care in partnership with leading health systems, ... to receive a strategic investment from Welsh, Carson, ... care investment firm. Emerus partners with ... and ambulatory clinical services to communities across a ...
(Date:9/1/2015)... -- Sleep Specialists, LLC a medical device company ... Solutions, a leader in digital health and chronic ... and cost reduction program for patients with Obstructive ... chronic medical condition characterized by periods of interrupted ... risk for cardiovascular disease, hypertension, stroke, congestive heart ...
(Date:9/1/2015)... RIVER, Mass. , Sept. 1, 2015   ... an additional 120,000 square feet in Olive Branch, ... Olive Branch facility has added the ... warehousing space. "This expansion gives us the ... Karl Neuberger , President of Millstone MS. "Two and a ...
Breaking Medicine Technology:Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3Sleep Specialists, LLC and HGE Health Care Solutions Announce Comprehensive Sleep Program 2Millstone Medical Outsourcing Announces Olive Branch Expansion 2
... NEW YORK, Jan. 12, 2011 InstaCare Corp. ... prescription and non-prescription diagnostics, home testing products for ... direct to patient diabetes programs, and a leading ... technologies, today announced that the company,s Board of ...
... 2011 At the 29th Annual J.P. Morgan Healthcare Conference, ... that based on a preliminary review of 2010 results, it ... more than $3.5 billion compared to 2009. Adjusted cash earnings ... the midpoint of the company,s latest forecast of $3.37 to ...
Cached Medicine Technology:InstaCare Corp. Announces 2011 Genstrip Guidance Report Penned by William Walling, CFA 2Watson Announces Preliminary Financial Performance for FY 2010 2Watson Announces Preliminary Financial Performance for FY 2010 3Watson Announces Preliminary Financial Performance for FY 2010 4
(Date:9/1/2015)... ... 2015 , ... e-Spirit Inc., a leading supplier of content ... Management System with new capabilities and enhancements designed to support the recently announced ... well on their way to achieving digital transformation with less time and less ...
(Date:9/1/2015)... York, New York (PRWEB) , ... September 01, 2015 , ... ... Zecurion Zlock Mac , its groundbreaking new version of endpoint DLP developed specifically ... of Zlock Mac, in which more than 100 IT and information security professionals had ...
(Date:9/1/2015)... Boston, MA (PRWEB) , ... September 01, 2015 , ... ... the little-known and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), will be the beneficiary of ... has the same mission – to raise awareness of the FSH Society and further ...
(Date:9/1/2015)... ... September 01, 2015 , ... Agriculture innovation, urban farming, local ... the topics to be discussed at Seedstock’s 4th Annual Sustainable Agriculture Conference : ... San Diego. , In addition to keynotes Pierre Sleiman, founder and CEO of ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... Qualification of Laboratory Instruments in accordance with GMP requirements“ , featuring Ed Szczesny ... October 6th, 2015 at 11:00 EDT (15:00 GMT). , Calibration, qualification, and ...
Breaking Medicine News(10 mins):Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:Zecurion Announces Endpoint Security for Mac 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 2Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 3Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 4Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 5Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2
... See Strength in Overall Business Trends in Difficult ... Economic Environment, ... the opening of the first franchisee-owned Medifast,Weight Control Center in the Baltimore, ... in the Festival at Bel Air Shopping,Center. This marks a milestone for ...
... Treatment Cleared for,Patients Who Have Not Benefited From ... Neuronetics, Inc., a,privately-held medical device company and ... that the U.S. Food and Drug Administration,(FDA) has ... for the treatment of depression. NeuroStar TMS Therapy(R) ...
... Orthopedics, Inc. today,announced the first human use of ... The landmark case was performed by Dr. Karin,Buttner-Janz, ... the Vivantes,Clinic in Berlin, Germany, and involved a ... developed symptomatic facet joint,degeneration. "Generally in this situation ...
... Launch of TransForce(R)2 Arch Developer ... ... Inc., a,leading global manufacturer of orthodontic products, laboratory services,and continuing education ... launch of their new and improved,TransForce2 Arch Developer Appliances. Two styles ...
... SectorWatch.biz announces the,availability of MarketStats for organic food ... relative to the healthy food market.,MarketStats offers a ... investors to respond with articles and opinions on ... http://www.SectorWatch.biz -- a,division of FiSpace.net, a ...
... License to Wyeth (NYSE:,WYE) and Elan Pharma International ... Neurosciences,Inc. (OTC Bulletin Board: ILNS), a biopharmaceutical company ... treatment and,prevention of Alzheimer,s disease (AD), announced today ... a top-tier global pharmaceutical company,regarding the right to ...
Cached Medicine News:Health News:Medifast Announces Opening of First Franchise Clinic 2Health News:Medifast Announces Opening of First Franchise Clinic 3Health News:Medifast Announces Opening of First Franchise Clinic 4Health News:Medifast Announces Opening of First Franchise Clinic 5Health News:FDA Clears NeuroStar(R) TMS Therapy for the Treatment of Depression 2Health News:FDA Clears NeuroStar(R) TMS Therapy for the Treatment of Depression 3Health News:FDA Clears NeuroStar(R) TMS Therapy for the Treatment of Depression 4Health News:FDA Clears NeuroStar(R) TMS Therapy for the Treatment of Depression 5Health News:Archus Orthopedics Performs First Facet Replacement Procedure With an Artificial Disc 2Health News:The Next Generation of Arch Expansion has Arrived 2Health News:SectorWatch.biz Issues MarketStats for Healthy and Organic Companies ORGC, DF, WFMI, LWAY, COIN, and TOF 2Health News:Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company an Option to License Certain Alzheimer's Patents and Patent Applications 2Health News:Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company an Option to License Certain Alzheimer's Patents and Patent Applications 3Health News:Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company an Option to License Certain Alzheimer's Patents and Patent Applications 4
... HT is designed for extended temperatures. ... ideal for applications such as DNA ... Incubator/Shaker HT is available as a ... three microplates. Iems Incubator/Shaker HT including ...
... are designed to give reliable performance for all ... on/off button, power supply socket and fuse holder ... unit. The speed knob is located on the ... from a minimum 950 rpm to a maximum ...
... only four-color, automated benchtop flow cytometry system ... sorting. Designed specifically to support a wide ... software instrument control, auto-sample loading, and push-button ... FACSCalibur is fully modular so it can ...
... cytometer for any kind of cell ... CyFlow SL analyzes forward and side ... to 3 fluorescence channels. Data acquisition, ... with a PC or laptop employing ...
Medicine Products: